Treatable traits in the NOVELTY study: prevalence, patterns and relationship with physician-assessed severity
Alvar Agusti, Eleni Rapsomaniki, Richard Beasley, Rod Hughes, Hana Müllerová, Alberto Papi, Ian D Pavord, Rosa Faner
European Respiratory Journal 2021 58: OA1289; DOI: 10.1183/13993003.congress-2021.OA1289
Alvar Agusti
1Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain
Eleni Rapsomaniki
2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
Richard Beasley
3Medical Research Institute of New Zealand, Wellington, New Zealand
Rod Hughes
2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
Hana Müllerová
2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
Alberto Papi
4Respiratory Medicine Unit, Dept of Medical Sciences, Università di Ferrara, Ferrara, Italy
Ian D Pavord
5Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
Rosa Faner
6IDIBAPS, Centro de Investigación Biomedica en Red M.P., Barcelona, Spain
Vol 58 Issue suppl 65
Table of Contents
Treatable traits in the NOVELTY study: prevalence, patterns and relationship with physician-assessed severity
Alvar Agusti, Eleni Rapsomaniki, Richard Beasley, Rod Hughes, Hana Müllerová, Alberto Papi, Ian D Pavord, Rosa Faner
European Respiratory Journal Sep 2021, 58 (suppl 65) OA1289; DOI: 10.1183/13993003.congress-2021.OA1289
Treatable traits in the NOVELTY study: prevalence, patterns and relationship with physician-assessed severity
Alvar Agusti, Eleni Rapsomaniki, Richard Beasley, Rod Hughes, Hana Müllerová, Alberto Papi, Ian D Pavord, Rosa Faner
European Respiratory Journal Sep 2021, 58 (suppl 65) OA1289; DOI: 10.1183/13993003.congress-2021.OA1289